IQP-VV-102, A Novel Proprietary Composition for Weight Reduction: A Double-Blind Randomized Clinical Trial for Evaluation of Efficacy and Safety,” Evidence-Based Complementary and Alternative Medicine: http://dx.

One limitation is that it was performed over a short period of only 12 weeks, with no follow-up conducted after the study was finished and no weight maintenance phase after the initial weight loss. Such weight loss due to the intake of IQP-AE-103 is considered to be of clinical relevance as European Medicines Agency associates a weight loss of 5% or more with a decrease of disease risk factors associated with overweight and obesity [ 38].

Unfortunately, although obesity stems from consuming more calories than the body burns, more than 80% of overweight and obese individuals have trouble losing and maintaining weight loss through diet and exercise alone.

As food exits the stomach more slowly, the complex may delay the intestine’s absorption of glucose, helping to reduce the appetite and sustain feelings of satiety. One hundred and eight (108) generally healthy, overweight, to moderately obese (BMI ≥25 and <35 kg/m 2) male and female volunteers between 18 and 65 years of age participated in the study. To evaluate a potential effect of IQP-AE-103 on food/energy intake, quantification of actual calorie intake by recording food consumption at an “ad libitum” lunch may be considered in future studies.L-Arabinose works by inhibiting the hydrolysis of sugar (sucrose) to glucose and fructose by intestinal sucrase, thus reducing glucose absorption in the intestine. Zaluvida Group has conducted more than 300 clinical studies on natural products and has developed a wealth of biotechnical health solutions, some of which have been commercialised by InQpharm North America (see Figure 1).

That is why I chose to have Trademark Elite to register the trademark for my award-winning law blog. Hunger Buddy does not contain any ingredient of animal origin and has no added artificial, flavourings, salt or preservatives. In summary, the study results provide the first promising evidence that the intake of IQP-AE-103 causes weight loss in overweight and moderately obese subjects in conjunction with a mild hypocaloric diet. Subgroup analysis showed that although both IQP-AE-103 high- and low-dose consumptions led to significant weight loss in overweight subjects, for moderately obese subjects, only high dose caused a significant body weight reduction.A. da Silva, “Inulin-type fructans: a review on different aspects of biochemical and pharmaceutical technology,” Carbohydrate Polymers, vol. As per recently published public health guidelines of National Institute for Health and Care Excellence and a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Obesity Society, losing 3% of baseline body weight is already associated with health benefits [ 9– 11]. Effects of moderate and subsequent progressive weight loss on metabolic function and adipose tissue biology in humans with obesity,” Cell Metabolism, vol.

T. Macfarlane, “Variation in human intestinal microbiota with age,” Digestive and Liver Disease, vol. As such, results obtained in the current study, primarily evaluating weight loss, on IQP-AE-103’s effect on appetite sensations remain exploratory. During the intervention period, no significant changes in fasting blood glucose and HbA1c levels were observed between the study groups.imply that inulin may also possess a fat-binding property besides its known beneficial effect as prebiotic, which contributed to a lower triglyceride and cholesterol levels in rats fed with high fat diet in the experiments [ 49]. Mean body weight changes over the study course are presented in Figure 2 (percentage relative to baseline) and Table 3 (kg loss from baseline), respectively.